A Agilent Technologies Inc.

Agilent Technologies Inspires at ASMS 2017 with Innovative Technology Solutions

Agilent Technologies Inc. (NYSE: A) today announced that it will showcase a range of new and innovative technology solutions at the American Society for Mass Spectrometry (ASMS) Conference being held June 3 through June 8 in Indianapolis, Indiana. New instruments, software, and services build on Agilent’s leadership in mass spectrometry and 50-year heritage in analytical technology.

“ASMS is a highlight for Agilent, and an excellent opportunity to showcase our continued dedication to technological innovation,” said Monty Benefiel, vice president and general manager of Agilent’s Mass Spectrometry Division. “Our customer events at ASMS are designed to demonstrate that we are always striving to meet and exceed expectations, foster productivity, help our customers succeed, and endeavor to make the world we live in a better, safer place.”

Agilent will host a variety of events including customer symposiums, scientific seminars, and breakfast meetings. The keynote speaker at Agilent’s Innovation Symposium customer event will be distinguished scientist Kevin Bateman, Ph.D., from Merck Research Labs who will present his work using mass spectrometry in biotherapeutic discovery and development. Dr. Bateman’s keynote will be followed by three parallel sessions from Agilent users in the areas of biological research, pharma and biopharma, and food and environmental segments.

Agilent will showcase new and existing products across its portfolio of ICP-MS, LC/MS, and GC/MS instruments and supplies. The InfinityLab Series LC/MSD single quadrupole LC/MS will debut at the conference. Its stackable design saves bench space without compromising performance and, when coupled with OpenLAB CDS, enables customers in QC environments to meet rigorous compliance standards. The new LC/MSD systems also support Cerno Bioscience’s MassWorks which facilitates increased mass accuracy by up to 100x and is a powerful, easy-to-use tool for unknown elemental composition determination of separated compounds in pharmaceutical, chemical, consumer product, food safety and organic synthesis laboratories.

Also on show at ASMS will be a full workflow solution for biopharma featuring the recently released AdvanceBio 6545XT LC/Q-TOF LC/MS with BioConfirm B.09, the AdvanceBio Peptide Plus LC column for peptide separations, and new applications in AssayMAP automated sample prep. Exciting additional announcements regarding new LC/MS and GC/MS products and solutions will also be made during the conference.

ASMS attendees are invited to visit Agilent’s Exhibition Booth 600 at the Indianapolis Convention Center and to spend time at the Agilent Hospitality Suite at the JW Marriott, Grand Ballroom 6, Monday, Tuesday and Wednesday evening from 8:00-10:30 p.m.

Agilent is a corporate member of ASMS and a co-sponsor of the annual event. Follow Agilent at ASMS on Twitter, using the conference hashtag: #ASMS2017.

About Agilent’s Mass Spectrometry Technologies

Agilent is the global leader in mass spectrometry, with powerful, reliable solutions for diverse applications such as pharmaceutical, environmental, and clinical research as well as toxicology and food testing. The company’s mass spectrometers work seamlessly with its industry-leading sample preparation solutions, separation columns and application-specific software, all backed by the Agilent CrossLab services team. For more information, visit Agilent’s mass spectrometry website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
01/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch